Advanced Medical Solutions Dividends - AMS

Advanced Medical Solutions Dividends - AMS

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Advanced Medical Solutions Group Plc AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change Price Change % Stock Price Last Trade
2.00 0.88% 230.00 16:35:04
Open Price Low Price High Price Close Price Previous Close
228.50 226.50 231.50 230.00 228.00
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Advanced Medical Solutions AMS Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
16/09/2020InterimGBX0.531/12/201931/12/202024/09/202025/09/202023/10/20200
11/03/2020FinalGBX1.0531/12/201831/12/201928/05/202029/05/202019/06/20201.55
11/09/2019InterimGBX0.531/12/201831/12/201926/09/201927/09/201925/10/20190
13/03/2019FinalGBX0.931/12/201731/12/201823/05/201924/05/201914/06/20191.32
12/09/2018InterimGBX0.4231/12/201731/12/201828/09/201829/09/201826/10/20180
14/03/2018FinalGBX0.7531/12/201631/12/201724/05/201825/05/201815/06/20181.1
13/09/2017InterimGBX0.3531/12/201631/12/201728/09/201729/09/201727/10/20170
14/03/2017FinalGBX0.6231/12/201531/12/201625/05/201726/05/201716/06/20170.92
14/09/2016InterimGBX0.331/12/201531/12/201629/09/201630/09/201628/10/20160
16/03/2016FinalGBX0.5531/12/201431/12/201519/05/201620/05/201610/06/20160.8
09/09/2015InterimGBX0.2531/12/201431/12/201501/10/201502/10/201530/10/20150
04/03/2015FinalGBX0.4831/12/201331/12/201407/05/201508/05/201529/05/20150.7
10/09/2014InterimGBX0.2231/12/201331/12/201401/10/201403/10/201431/10/20140
06/03/2014FinalGBX0.4131/12/201231/12/201330/04/201402/05/201428/05/20140.6
11/09/2013InterimGBX0.1931/12/201231/12/201302/10/201304/10/201301/11/20130
06/03/2013FinalGBX0.3531/12/201131/12/201201/05/201303/05/201328/05/20130.52
05/09/2012InterimGBX0.1731/12/201131/12/201203/10/201205/10/201202/11/20120
07/03/2012FinalGBX0.3131/12/201031/12/201116/05/201218/05/201215/06/20120.45
07/09/2011InterimGBX0.14531/12/201031/12/201105/10/201107/10/201104/11/20110
08/03/2011FinalGBX0.3831/12/200931/12/201011/05/201113/05/201110/06/20110.38

Top Dividend Posts

DateSubject
09/12/2020
21:53
wetdream: dealit, I have a love/hate relationship with AMS... I’ve always thought of them as a well-run, if undynamic, company with a solid product range and in a pretty ‘fireproofR17; business sector. A bit too dependent on acquisitions (that I struggle to appreciate) but hey-ho, ‘steady as she goes’. But then along came Trump with his ‘America First’ campaign in the middle of the pandemic and AMS just got left behind. Not entirely their fault, but irritating that it’ s set them back as you point out at least 12 months. They’ve done well to hold on to some quality funds as supporters, so I guess extra patience is required.
09/12/2020
15:42
dealit: wetdream-I have posted part of an announcement from earlier in the year and feel that AMS S/P should head north on FDI approval IMHO.---- The LiquiBand® XL critical pilot study has been completed with three different formulations successfully meeting our objective of 14-day wear time. However, some of the variants demonstrated extended set time. The lead formulation, which we believe maximises our potential for long term commercial success on all product features, is an accelerated formulation of LiquiBand® that will require additional stability and biocompatibility data along with a repeat of the clinical study as part of the FDA filing. The additional work required on this lead formulation means that we now expect to file for 510K approval in the first quarter of 2021. We expect the financial impact of this delayed approval to be offset by the stronger than anticipated LiquiBand® market share improvement and short term commercial agreements with US hospitals to encourage additional LiquiBand® adoption in the run up to the LiquiBand® XL approval. Once approved, LiquiBand® XL will allow entry into the market for care of larger wounds and unlock further growth potential in the LiquiBand® business with all partners.
23/11/2020
16:31
energeticbacker: Advanced Medical Solutions acquires Raleigh Adhesive Coatings, reports Investor's Champion. For the 6 months ending 31 October Raleigh generated revenue of £3.9m and operating profit of £0.8m, compared to the prior year’s loss of £0.3m. The £22m acquisition cost therefore represents quite a multiple, suggesting AMS thinks highly of this business.
20/11/2020
16:49
energeticbacker: AMS received CE mark approval for its Silicone PHMB Foam Dressing, which sits alongside the previously US approval for this product. AMS has had a tough time over the pandemic which has led to the deferral of elective surgeries and woundcare clinics, however, according to Investor's Champion this innovative business remains in good shape and should continue to thrive when markets recover.
16/9/2020
07:35
dealit: Results out today, still making a profit and paying a dividend. Very creditable performance considering Covid 19 times we are going through IMHO.
04/8/2020
06:37
dealit: Let us hope this announcement as a positive effect on the s/p:- Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that it has been granted UK and US patents for the LiquiBand® Exceed range, providing protection until 2034. The design of the applicator, tip and the raw materials used to manufacture the device has allowed it to be distinguished as a novel, patentable technology. These patents provide long-term protection on a core growth driver for the global LiquiBand® portfolio, covering 30-35% of the current product range. In addition, the UK patent will provide an additional tax benefit to the Group via the UK patent box scheme that is expected to reduce the effective tax rate for the Group by between 1% and 2% throughout the patent life. Chris Meredith, Chief Executive Officer of AMS, commented: "With end sales demand for LiquiBand® in the US showing early signs of recovery demonstrated by market share gains in the first quarter of 2020, these newly granted patents will further strengthen and protect growth in our core markets. They also highlight AMS's continued ability to design, develop and sell innovative, patentable technology."
24/6/2020
15:02
wetdream: AMS - the share the market forgot. How restful it must be, knowing that NOONE is talking about you. Zzzzzz
17/5/2020
01:20
buywell3: USA It may take up to 4 months to reschedule surgeries and medical procedures htTps://www.cnbc.com/2020/04/29/it-may-take-up-to-4-months-to-reschedule-surgeries-and-medical-procedures.html UK NHS BRITISH NHS SURGERY BACKLOG COULD TAKE MANY MONTHS TO WORK THROUGH, HEALTH EXPERTS WARN htTps://www.newsweek.com/british-nhs-surgery-backlog-could-take-many-months-work-through-health-experts-warn-1504135 Reasonable this 4 months timescale looks set to be the norm for other countries However that depends upon there NOT being a second wave of Covid-19 cases from now to end of August . Something buywell thinks is very unlikely based upon wave timings of approx 4 months in the Spanish Flu Pandemic 1918 to 1918 where there were 3 waves over approx 13 months duration. That was also a virus . The way I read what has been said AMS could take a turnover hit of circa 5% per month of postponements , which started in earnest circa Mid March htTps://pharmaintelligence.informa.com/resources/product-content/us-hospitals-cancel-elective-surgeries-team-up-with-medtechs-to-find-remote-monitoring-solutions buywell is now of the opinion that it seems not unreasonable that approx 4 months to 5 months of elective surgery procedures could be lost from march 14th . If another wave of Covid-19 cases kicks off , which buywell is of the opinion as being highly likely V Spanish Flu scenario Then elective surgeries will IMO be kicked into touch once again which effectively would mean they would never have restarted in any meaningful way from their first suspension date of March 14th ( reason being as explained in first two links) This is pretty serious stuff for Hospitals in the USA , many of which have laid off staff as they depend on getting monies in per patient operation ie not like NHS. Will the Democrats push for a USA NHS model ? buywell doubts it as the lobbyists ie BIG Pharma , tell the politicians over there what to do. IMO dyor
09/4/2020
20:35
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a Twin Petes Investing Podcast a few days ago and AMS was one of the Stocks that we discussed. We also talked in depth about the current situation in the Markets and how we reckon things could play out. Anyway, if you use Apple or Audioboom you can find them under the 'Conkers Corner' Channel (you want TPI Podcast 20) and you can find it on Soundcloud at the link below. Ideal Easter listening whilst you are locked away !! Cheers, WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheelidealer-20-potential-domino-effects-of-covid19-conkers3-new-strategy-ams-azn
04/4/2020
09:57
masurenguy: "With £65m of cash in the bank and no debt at 31 December 2019, AMS is in robust financial condition. Furthermore, in the unlikely event that it’s needed, there is also an undrawn unsecured £80m credit facility. AMS is committing to a final dividend for 2019 of 1.05p per share, costing approx. £2.25m." https://fundamentalasset.com/encouraging-news-week/
ADVFN Advertorial
Your Recent History
LSE
AMS
Advanced M..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 15:33:55